Compositions and methods for the treatment of cancers through inhibition of cell-in-cell phenomenon

EP4724503A2Pending Publication Date: 2026-04-15INST FOR CANCER RES D B A THE RES INSTITUE OF FOX CHASE CANCER CENT +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
INST FOR CANCER RES D B A THE RES INSTITUE OF FOX CHASE CANCER CENT
Filing Date
2024-06-10
Publication Date
2026-04-15

AI Technical Summary

Technical Problem

Current cancer treatments face challenges in eliminating residual disease due to the ability of cancer cells to evade therapy by hiding within stromal cells, leading to relapse, as the molecular mechanisms underlying this phenomenon, particularly the Cell-in-Cell (CIC) process, are not well understood.

Method used

The development of combination regimens involving BTK inhibitors and CXCR4 antagonists to modulate the CIC internalization process, thereby reducing the occurrence of residual disease by inhibiting pathways such as the CXCL12-CXCR4 axis, and using ex vivo cell culture systems to identify effective agents.

Benefits of technology

This approach enhances the therapeutic effects of BTK inhibitors, promotes long-term remission, and reduces the risk of minimal residual malignant disease by preventing cancer cells from evading treatments and minimizing undesirable side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000056_0000
    Figure 00000056_0000
  • Figure 00000057_0000
    Figure 00000057_0000
  • Figure 00000057_0001
    Figure 00000057_0001
Patent Text Reader

Abstract

Compositions and methods for the treatment of cancers through the inhibition of Cell-in-Cell Phenomenon are provided herein. Also provided are compositions and methods for modulating the CIC internalization process and identification of agents which modulate the same.
Need to check novelty before this filing date? Find Prior Art